Molecular cloning, expression and enzymatic assay of pteridine reductase 1 from Iranian lizard leishmania

ABSTRACT

Currently, there are no effective vaccines against leishmaniasis, and treatment using pentavalent antimonial drugs is occasionally effective and often toxic for patients. The PTR1 enzyme, which causes antifolate drug resistance in Leishmania parasites encoded by gene pteridine reductase 1 [ptr 1]. Since Leishmania lacks pteridine and folate metabolism, it cannot synthesize the pteridine moiety from guanine triphosphate. Therefore, it must produce pteridine using PTR1, an essential part of the salvage pathway that reduces oxidized pteridines. Thus, PTR1 is a good drug-target candidate for anti-Leishmania chemotherapy. The aim of this study was the cloning, expression, and enzymatic assay of the ptrl gene from Iranian lizard Leishmania as a model for further studies on Leishmania. Promastigote DNA was extracted from the Iranian lizard Leishmania, and the ptrl gene was amplified using specific primers. The PCR product was cloned, transformed into Escherichia coli strain JM109, and expressed. The recombinant protein [PTR1 enzyme] was then purified and assayed. Ptr1 gene was successfully amplified and cloned into expression vector. Recombinant protein [PTR1 enzyme] was purified using affinity chromatography and confirmed by Western-blot and dot blot using anti-Leishmania major PTR1 antibody and anti-T7 tag monoclonal antibody, respectively. The enzymatic assay was confirmed as PTR1 witch performed using 6-biopterin as a substrate and nicotinamide adenine dinucleotide phosphate as a coenzyme. Iranian lizard Leishmania ptr1 was expressed and enzymatic assay was performed successfully